01840nam 2200373 450 991059791540332120230220214134.0(CKB)4920000000094882(NjHacI)994920000000094882(EXLCZ)99492000000009488220230220d2018 uy 0engur|||||||||||txtrdacontentcrdamediacrrdacarrierMarine Compounds and Cancer /edited by Friedemann Honecker, Sergey A. DyshlovoyBasel :MDPI - Multidisciplinary Digital Publishing Institute,2018.1 online resource (v, 110 pages)3-03842-765-9 The very first marine-derived anticancer drug, Cytarabine (aka Ara-C, Cytosar-U(R)), was approved by the FDA in 1969 for the treatment of leukemia. At the beginning of 2021, the list of approved marine-derived anticancer drugs consists of nine substances, five of which received approval within the last two years, demonstrating the rapid evolution of the field. The current book is a collection of scientific articles related to the exponentially growing field of anticancer marine compounds. These articles cover the whole field, from agents with cancer-preventive activity, to novel and previously characterized compounds with anticancer activity, both in vitro and in vivo, as well as the latest status of compounds under clinical development.CancerRadiotherapyMarine toxinsCancerRadiotherapy.Marine toxins.615.945Honecker FriedemannDyshlovoy Sergey A.NjHacINjHaclBOOK9910597915403321Marine Compounds and Cancer2947621UNINA